Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by André Pèlegrin
Last modified by standudu
Group name EquipeAP
Item Type Journal Article
Title [Mimicking polyclonal immune response in therapy: from combination of two monoclonal antibodies to oligoclonal antibody-based mixtures]
Creator Larbouret et al.
Author Christel Larbouret
Author Marie-Alix Poul
Author Thierry Chardès
Abstract Monoclonal antibodies have revolutionized the treatment of many diseases, but their clinical effectiveness remains limited in some cases. Associations of antibodies binding to the same target (homo-combination) or to several different targets (hetero-combination), thereby mimicking a polyclonal humoral immune response, have demonstrated a therapeutic improvement in pre-clinical and clinical trials, mainly in the field of oncology and infectious diseases. The combinations increase the efficacy of the biological responses and override resistance mechanisms observed with antibody monotherapy. The most common method of formulating and administering antibody combinations is a separate formulation, with sequential injection of each antibody as individual drug substance. Alternatively, combined formulations are developed where the separately-produced antibodies are mixed before administration or produced simultaneously by a single cell line, or a mixture of cell lines as a polyclonal master cell bank. The regulation, the toxicity and the injection sequence of these oligoclonal antibody-based mixtures remain points to be clarified and optimized for a better therapeutic effect.
Publication Medecine Sciences: M/S
Volume 35
Issue 12
Pages 1083-1091
Date Dec 2019
Journal Abbr Med Sci (Paris)
Language fre
DOI 10.1051/medsci/2019216
ISSN 1958-5381
Short Title [Mimicking polyclonal immune response in therapy
Library Catalog PubMed
Extra 00000 PMID: 31903921
Date Added 2020/02/17 - 11:34:50
Date Modified 2020/02/17 - 11:59:54
Notes and Attachments PubMed entry (Attachment)
Texte intégral (Attachment)


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés